← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,486개
ADCBiologicstalePfizerPhase 2

PF-08634404 (PF-08634404)

Urothelial Cancer; Advanced/Metastatic Urothelial Cancer · Urothelial Cancer

#UrothelialCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 11상태 RECRUITING
ADCBiologicstaleRemeGen Co., Ltd.Phase 2

disitamab vedotin (Disitamab Vedotin, RC48, RC48 + Carboplatin)

Ovarian Cancer; HER2 · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 11상태 RECRUITING
ADCBiologicstaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Combined With Sintilimab)

Gastric Cancer · Gastric Cancer

#GastricCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 10상태 ACTIVE
ADCBiologicstaleCuris, Inc.Phase 1

Emavusertib (Emavusertib)

Metastatic Biliary Tract Cancer; Metastatic Biliary Tract Carcinoma · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 10상태 RECRUITING
CGTBiologicstaleChongqing University Cancer Hos…Phase 2

Oncolytic Virus H101 (Oncolytic Virus H101)

Rectal Neoplasms; Rectal Adenocarcinoma · Rectal Neoplasms

#RectalNeoplasms#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 10상태 RECRUITING
ADCBiologicstaleQuantumLeap Healthcare Collabor…Phase 2

Amcenestrant (Amcenestrant)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 42.3%임상시험 9상태 RECRUITING
ADCBiologicstaleCSPC ZhongQi Pharmaceutical Tec…Phase 3

DP303c (DP303c)

HER2-positive Breast Cancer · Localized Advanced or Metastatic Gastric

#LocalizedAdvancedorMetastaticGas#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 9상태 RECRUITING
ADCBiologicstaleQuantumLeap Healthcare Collabor…Phase 2

Lasofoxifene (Lasofoxifene)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 9상태 RECRUITING
ADCBiologicstaleDaiichi SankyoPhase 3

R-DXd (R-DXd)

Solid Cancer · Solid Cancer

#SolidCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+1
임상시험 9상태 RECRUITING
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

R-DXd (Raludotatug Deruxtecan, Raludotatug Deruxtecan (R-DXd))

Gastrointestinal Cancer · Gastrointestinal Cancer

#GastrointestinalCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 9상태 RECRUITING
AntibodystaleXencor, Inc.Phase 2

XmAb20717 (XmAb20717)

Biliary Tract Cancer · Melanoma

#Melanoma#Antibody#Phase2#항체#면역항체+3
임상시험 9상태 RECRUITING
ADCBiologicstaleCelldex TherapeuticsPreclinical

glembatumumab vedotin (glembatumumab vedotin)

Metastatic gpNMB Expressing Triple Negative Breast Cancer · Melanoma

#Melanoma#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 21%임상시험 9상태 ACTIVE
AntibodystaleMacroGenicsPhase 1

lorigerlimab (lorigerlimab)

Advanced Solid Tumor; Castration-Resistant Prostatic Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#항체#면역항체+3
임상시험 9상태 ACTIVE
CGTBiologicstaleTILT Biotherapeutics Ltd.Phase 1

Oncolytic virus Plus Anti-PD1 and Chemotherapy (Oncolytic virus Plus Anti-PD1 and Chemotherapy)

Pancreatic Cancer · Pancreatic Cancer

#PancreaticCancer#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 8상태 RECRUITING
ADCBiologicGenmabPhase 3

Rina-S (Rina-S)

High Grade Epithelial Ovarian Cancer; High Grade Serous Ovarian Cancer · Platinum-resistant Ovarian Cancer

#Platinum-resistantOvarianCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
임상시험 8상태 RECRUITING
ADCBiologicstaleGenmabApproved

TIVDAK (TIVDAK)

Cervical Cancer · Cervical Cancer

#CervicalCancer#ADC#Approved#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 23.8%임상시험 8상태 RECRUITING
AntibodyRochePhase 3

atezolizumab (Tecentriq, Atezolizumab and Recombinant Human Hyaluronidase)

Lung Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8 · Lung Non-Small Cell Carcinoma

#LungNon-SmallCellCarcinoma#Antibody#Phase3#항체#면역항체+3
효능 ORR 10.5%임상시험 7상태 RECRUITING
AntibodystaleEli LillyPhase 2

Cetuximab/Erbitux (Cetuximab/Erbitux)

Cancer · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 52.2%임상시험 7상태 ACTIVE
AntibodystaleAstraZenecaPhase 3

MEDI4736 (Durvalumab, Durvalumab (MEDI4736))

Non-small Cell Lung Cancer · Non Small Cell Lung Carcinoma NSCLC

#NonSmallCellLungCarcinomaNSCLC#Antibody#Phase3#항체#면역항체+3
효능 ORR 44%임상시험 7상태 RECRUITING
AntibodyHoffmann-La RochePhase 3

Emactuzumab (Emactuzumab)

Cancer · Cancer

#Cancer#Antibody#Phase3#항체#면역항체+2
임상시험 7상태 RECRUITING

20 / 75 페이지

← 이전다음 →